Anti-tigit antibody and use thereof

An antibody or antigen-binding fragment thereof capable of specifically binding to TIGIT, wherein the antibody or antigen-binding fragment thereof comprises:

• (a) a VH CDR1 or variant thereof, a VH CDR2 or variant thereof and a VH CDR3 or variant thereof comprised in the heavy chain variable region (VH) as set forth in SEQ ID NO:
• 4;
• and/or, a VL CDR1 or variant thereof, a VL CDR2 or variant thereof, and a VL CDR3 or variant thereof comprised in the light chain variable region (VL) as set forth in SEQ ID NO:
• 8;
• or,
• (b) a VH CDR1 or variant thereof, a VH CDR2 or variant thereof and a VH CDR3 or variant thereof comprised in the heavy chain variable region (VH) as set forth in SEQ ID NO:
• 12;
• and/or, a VL CDR1 or variant thereof, a VL CDR2 or variant thereof, and a VL CDR3 or variant thereof comprised in the light chain variable region (VL) as set forth in SEQ ID NO:
• 16;
• wherein, the variant has a substitution, deletion or addition of one or several amino acids (e.g., a substitution (such as conservative substitution), deletion or addition of 1, 2 or 3 amino acids) as compared to the sequence from which it is derived;
• preferably, the substitution is a conservative substitution;
• preferably, the antibody or antigen-binding fragment thereof comprises:
• (a) three CDRs comprised in the heavy chain variable region (VH) as set forth in SEQ ID NO:
• 4;
• and/or, three CDRs comprised in the light chain variable region (VL) as set forth in SEQ ID NO:
• 8;
• or,
• (b) three CDRs comprised in the heavy chain variable region (VH) as set forth in SEQ ID NO:
• 12;
• and/or, three CDRs comprised in the light chain variable region (VL) as set forth in SEQ ID NO:
• 16;
• preferably, the three CDRs comprised in the VH and/or the three CDRs comprised in the VL are defined by the Kabat, IMGT or Chothia numbering system.